We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

1 hedge funds and large institutions have $358 invested in Acceleron Pharma in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter

XLRN Hedge Fund Activity: Q2 2026 in Review

1 of the 8,365 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q2 2026, worth a combined $358 — unchanged from a quarter earlier.

Fund positioning in XLRN was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held Acceleron Pharma (XLRN) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $358 of Acceleron Pharma stock for Q2 2026, unchanged quarter-over-quarter.
  • 0 funds opened new Acceleron Pharma positions in Q2 2026 and 0 closed out.

Based on aggregated 13F filings for Q2 2026.